Layered Protection.
Defensible Moat.
BioMimetix's exclusivity is built on a four-layer strategy combining method-of-use patents, manufacturing IP, regulatory exclusivity, and proprietary clinical data.
Potential Regulatory Exclusivity
Subject to eligibility and approval, BMX-001 may qualify for applicable FDA regulatory exclusivities, including 7-year orphan-drug exclusivity for an approved orphan indication and, if approved as a new chemical entity, up to 5 years of NCE exclusivity.
Clinical Use Patents
Method-of-use patent protection in key jurisdictions, with certain US patents potentially eligible for patent-term extension following regulatory approval.
Manufacturing Know-How
Proprietary manufacturing trade secret — IP submission planned
Proprietary Clinical Data
Indication-specific data packages across 4 active programs
Patent Portfolio
| Program | Patent Type / Exclusivity | Jurisdiction | Status |
|---|---|---|---|
| BMX-001 | Composition of Matter | US | Granted (filed 2005) |
| BMX-001 | Methods of Use / Treatment | Key jurisdictions | Granted (filed 2018) |
| BMX-001 | Manufacturing / Synthesis | Key jurisdictions | Pending |
| BMX-201 / BMX-202 | Composition of Matter | Key jurisdictions | Pending (filed 2018) |
Regulatory Exclusivity
| Program | Patent Type / Exclusivity | Jurisdiction | Status |
|---|---|---|---|
| BMX-001 | Orphan Drug Designation — High-Grade Glioma | US | Granted |
| BMX-001 | Potential orphan exclusivity following approval | US | Upon approval |
| BMX-001 | Potential NCE exclusivity, if eligible | US | Upon approval |
| BMX-001 | Potential U.S. patent-term extension, if eligible | US | Upon approval |
Regulatory exclusivities are contingent upon FDA approval and eligibility. Patent-term extension is subject to applicable statutory requirements.
Patent and regulatory status is subject to change.